X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs CIPLA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA CIPLA ABBOTT INDIA/
CIPLA
 
P/E (TTM) x 36.6 37.6 97.4% View Chart
P/BV x 10.6 3.9 273.9% View Chart
Dividend Yield % 0.6 0.3 174.2%  

Financials

 ABBOTT INDIA   CIPLA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-17
CIPLA
Mar-17
ABBOTT INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs5,190622 834.5%   
Low Rs4,351458 949.4%   
Sales per share (Unadj.) Rs1,382.9181.9 760.5%  
Earnings per share (Unadj.) Rs130.212.9 1,011.5%  
Cash flow per share (Unadj.) Rs137.929.3 470.5%  
Dividends per share (Unadj.) Rs40.002.00 2,000.0%  
Dividend yield (eoy) %0.80.4 226.4%  
Book value per share (Unadj.) Rs652.7155.7 419.2%  
Shares outstanding (eoy) m21.25804.51 2.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 116.1%   
Avg P/E ratio x36.642.0 87.3%  
P/CF ratio (eoy) x34.618.4 187.7%  
Price / Book Value ratio x7.33.5 210.7%  
Dividend payout %30.715.5 197.7%   
Avg Mkt Cap Rs m101,373434,516 23.3%   
No. of employees `0003.123.0 13.4%   
Total wages/salary Rs m3,45326,338 13.1%   
Avg. sales/employee Rs Th9,531.96,349.1 150.1%   
Avg. wages/employee Rs Th1,119.91,143.0 98.0%   
Avg. net profit/employee Rs Th897.3449.3 199.7%   
INCOME DATA
Net Sales Rs m29,387146,302 20.1%  
Other income Rs m5762,287 25.2%   
Total revenues Rs m29,963148,589 20.2%   
Gross profit Rs m3,97324,758 16.0%  
Depreciation Rs m16413,229 1.2%   
Interest Rs m201,594 1.3%   
Profit before tax Rs m4,36512,222 35.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5981,798 88.9%   
Profit after tax Rs m2,76710,354 26.7%  
Gross profit margin %13.516.9 79.9%  
Effective tax rate %36.614.7 249.0%   
Net profit margin %9.47.1 133.0%  
BALANCE SHEET DATA
Current assets Rs m18,90687,370 21.6%   
Current liabilities Rs m6,29733,081 19.0%   
Net working cap to sales %42.937.1 115.6%  
Current ratio x3.02.6 113.7%  
Inventory Days Days6287 71.5%  
Debtors Days Days2262 34.7%  
Net fixed assets Rs m1,159111,567 1.0%   
Share capital Rs m2131,609 13.2%   
"Free" reserves Rs m13,657123,645 11.0%   
Net worth Rs m13,869125,254 11.1%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m20,638209,532 9.8%  
Interest coverage x215.08.7 2,479.9%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.40.7 203.9%   
Return on assets %13.55.7 236.8%  
Return on equity %19.98.3 241.3%  
Return on capital %31.68.5 372.0%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m051,066 0.0%   
Fx outflow Rs m017,678 0.0%   
Net fx Rs m033,388 0.0%   
CASH FLOW
From Operations Rs m3,07223,824 12.9%  
From Investments Rs m-1,554-13,127 11.8%  
From Financial Activity Rs m-898-13,239 6.8%  
Net Cashflow Rs m621-2,478 -25.0%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 7.9 12.2 64.8%  
FIIs % 0.1 23.7 0.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.1 26.2 65.3%  
Shareholders   18,270 161,166 11.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  PFIZER  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 19, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS